{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:17:07Z","timestamp":1790803027924,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ajo.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:32:37Z","timestamp":1763645557000},"page":"358-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical Efficacy of Biosimilar Switch of Adalimumab and Infliximab for Noninfectious Uveitis: Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-0476","authenticated-orcid":false,"given":"CHARLES","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MOHAMMAD","family":"AYOUBI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GEORGES","family":"ABOUKASM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SINAN","family":"ERSAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL","family":"ZHU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AMANDA","family":"WONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NICOLAS A","family":"YANNUZZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THOMAS A","family":"ALBINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2025.11.015_bib0001","first-page":"171","article-title":"Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update","volume":"131","author":"Prieto-Pena","year":"2021","journal-title":"Pol Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ajo.2025.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/imj.14215","article-title":"The use of biologic agents in the management of uveitis","volume":"49","author":"Trivedi","year":"2019","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.015_bib0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","article-title":"Adalimumab for the treatment of uveitis","volume":"13","author":"LaMattina","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0004","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1186\/s12913-019-4680-2","article-title":"Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis","volume":"19","author":"Mansell","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"8","key":"10.1016\/j.ajo.2025.11.015_bib0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2174\/1389203717666160226144618","article-title":"A comprehensive overview on biosimilars","volume":"17","author":"Kadam","year":"2016","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.ajo.2025.11.015_bib0006","unstructured":"Padda IS, Bhatt R, Parmar M. Biosimilars use in medicine for inflammatory diseases. StatPearls. 2025. Updated August 28, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574572\/."},{"key":"10.1016\/j.ajo.2025.11.015_bib0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2017.02.003","article-title":"Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-alpha agents in rheumatic diseases; a systematic review and meta-analysis","volume":"79","author":"Komaki","year":"2017","journal-title":"J Autoimmun"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.11.015_bib0008","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10198-014-0594-4","article-title":"Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison","volume":"15","author":"Baji","year":"2014","journal-title":"Eur J Health Econ"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.11.015_bib0009","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/s10198-014-0593-5","article-title":"Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis","volume":"15","author":"Baji","year":"2014","journal-title":"Eur J Health Econ"},{"issue":"12","key":"10.1016\/j.ajo.2025.11.015_bib0010","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/IAE.0000000000003626","article-title":"Anti-vascular endothelial growth factor biosimilars in ophthalmology","volume":"42","author":"Kaiser","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2025.11.015_bib0011","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/OPTH.S180393","article-title":"Biosimilars in ophthalmology: \u201cIs there a big change on the horizon?\u201d","volume":"12","author":"Sharma","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.11.015_bib0012","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2020.08.005","article-title":"Recurrence rates of inflammation after switching from the originator Infliximab to Biosimilar Infliximab-abda for noninfectious Uveitis","volume":"225","author":"Deaner","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0013","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/IIO.0000000000000530","article-title":"Comparison of reference and biosimilar medications for pediatric noninfectious uveitis","volume":"64","author":"Valikodath","year":"2024","journal-title":"Int Ophthalmol Clin"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0014","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/09273948.2023.2172591","article-title":"Clinical efficacy of biosimilar switch of adalimumab for management of Uveitis","volume":"32","author":"Murray","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.ajo.2025.11.015_bib0015","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/09273948.2023.2295544","article-title":"Efficacy and safety of switching from adalimumab originator to SB5, adalimumab biosimilar for noninfectious uveitis","volume":"32","author":"Song","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2025.11.015_bib0016","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3389\/fphar.2019.01468","article-title":"The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors","volume":"10","author":"Fabiani","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2025.11.015_bib0017","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajo.2020.10.013","article-title":"A systematic switch from originator Infliximab to Biosimilar Infliximab in patients with non-infectious uveitis","volume":"225","author":"Kumar","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.11.015_bib0018","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook."},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.ajo.2025.11.015_bib0020","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches the GRADE working group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ajo.2025.11.015_bib0023","unstructured":"Sch\u00fcnemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M.J, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from www.cochrane.org\/handbook."},{"issue":"3","key":"10.1016\/j.ajo.2025.11.015_bib0024","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3414\/ME12-01-0063","article-title":"The standardization of uveitis nomenclature (SUN) project. development of a clinical evidence base utilizing informatics tools and techniques","volume":"52","author":"Trusko","year":"2013","journal-title":"Methods Inf Med"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0026","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.rdc.2021.07.005","article-title":"Uveitis in children and adolescents","volume":"47","author":"Chang","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0027","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","article-title":"Rapid loss of efficacy of biosimilar infliximab in three patients with Behcet's disease after switching from infliximab originator","volume":"4","author":"Cantini","year":"2017","journal-title":"Eur J Rheumatol"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.015_bib0028","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14712598.2016.1198765","volume":"16","author":"Gentileschi","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.ajo.2025.11.015_bib0029","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1080\/19420862.2017.1337620","article-title":"Glycosylation Profile and Biological activity of Remicade(R) compared with Flixabi(R) and remsima(R)","volume":"9","author":"Lee","year":"2017","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.ajo.2025.11.015_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2025.103771","article-title":"Highly variable aggregation and glycosylation profiles and their roles in immunogenicity to protein-based therapeutics","volume":"114","author":"Sarsarshahi","year":"2025","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.ajo.2025.11.015_bib0031","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/mabs.32221","article-title":"Physicochemical characterization of Remsima","volume":"6","author":"Jung","year":"2014","journal-title":"MABS"},{"issue":"2","key":"10.1016\/j.ajo.2025.11.015_bib0032","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2017-211741","article-title":"Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0033","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","article-title":"Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study","volume":"65","author":"Benucci","year":"2017","journal-title":"Immunol Res"},{"issue":"7","key":"10.1016\/j.ajo.2025.11.015_bib0034","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar remsima","volume":"65","author":"Ben-Horin","year":"2016","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.015_bib0035","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the Pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.015_bib0036","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajo.2025.11.015_bib0037","article-title":"Impact of nonmedical switches from reference Infliximab to biosimilars on disease control within a rheumatology practice","author":"Jankowska","year":"2024","journal-title":"J Pharm Technol"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12969-019-0383-9","article-title":"Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis","volume":"17","author":"Miraldi Utz","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.ajo.2025.11.015_bib0039","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.15872","article-title":"Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis","volume":"6","author":"Ascef","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2352019","article-title":"Use of corticosteroids in non-infectious uveitis - expert consensus in Taiwan","volume":"56","author":"Chang","year":"2024","journal-title":"Ann Med"},{"issue":"8","key":"10.1016\/j.ajo.2025.11.015_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.70230","article-title":"Self-injection satisfaction and safety of CT-P17 (Yuflyma), a high-concentration adalimumab biosimilar, in patients with Crohn's Disease: a cross-sectional study","volume":"9","author":"Pan","year":"2025","journal-title":"JGH Open"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0042","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"key":"10.1016\/j.ajo.2025.11.015_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.917814","article-title":"Switching among biosimilars: a review of clinical evidence","volume":"13","author":"Allocati","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.015_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292231","article-title":"Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis","volume":"18","author":"Herndon","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.015_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40222-5","article-title":"Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis","volume":"13","author":"de Oliveira Ascef","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.015_bib0046","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/cpt.1836","article-title":"The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review","volume":"108","author":"Barbier","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.015_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/ph17101319","article-title":"The efficacy, safety, and persistence of therapy after non-medical switching from an originator adalimumab in inflammatory bowel disease: real-life experience from two tertiary centres","volume":"17","author":"Spataru","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"10.1016\/j.ajo.2025.11.015_bib0048","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.ajo.2025.11.015_bib0049","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","article-title":"Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study","volume":"54","author":"Lontai","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.015_bib0050","first-page":"613","article-title":"Effectiveness of non-medical switch from adalimumab Bio-originator to SB5 Biosimilar and from ABP501 Adalimumab Biosimilar to SB5 Biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study","volume":"41","author":"Scrivo","year":"2023","journal-title":"Clin Exp Rheumatol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:59:02Z","timestamp":1783025942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425006075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":49,"alternative-id":["S0002939425006075"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.11.015","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy of Biosimilar Switch of Adalimumab and Infliximab for Noninfectious Uveitis: Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}